CAS 65271-80-9|CAS 70476-82-3|Mitoxantrona [INN-Spanish]|Mitoxantron|mitoxantrone|Novantrone|Mitoxantrone HCl|Mitozantrone|DHAQ|Mitoxantronum [INN-Latin]|Dihydroxyanthraquinone|Novantron|DHAD|mitoxa...

基本信息

化学结构

分子式

C₂₂H₂₈N₄O₆

分子量

444.48092

精确质量

444.20088464

电荷

0

InChI

InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2

InChIKey

KKZJGLLVHKMTCM-UHFFFAOYSA-N

Canonic Smiles

OCCNCCNc1ccc(c2c1C(=O)c1c(C2=O)c(O)ccc1O)NCCNCCO

Isomeric Smiles

O=C1c2c(c(NCCNCCO)ccc2NCCNCCO)C(=O)c2c1c(O)ccc2O

计算属性

JChem

LogD (pH = 7.4)

-1.36

LogD (pH = 5.5)

-4.32

Log P

0.65

可自由旋转的化学键

12

质子供体

8

质子受体

10

里宾斯基五规则

false

Acid pKa

9.36

极化表面积

163.18

极化性

47.82

摩尔折射率

123.53

LOG S

-2.32

数据来源

学术数据

产品目录

数据来源

名称和标识

别名

MitoxantronMitoxantrona [INN-Spanish]MitozantroneMitoxantrone HClDHAQmitoxantroneMitoxantronum [INN-Latin]MitoxanthroneMitoxantrone dihydrochlorideDihydroxyanthraquinoneDHADMitozantrone hydrochlorideDHAQ HClMitoxantroneMitoxantrone 2HClMitoxantrone hydrochlorideNCI 301739BisantroneImmunexNimitoxantronNSC 279836Mitox1,4-Bis[(2-(2-hydroxyethylamino)ethyl)amino]-5,8-dihydroxyanthraquinoneMitoxantrone DihydrochlorideRalenovaNSC 301739NovatroneNovantrone1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione HydrochlorideNovantronCL 232315Mitoxantrone1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONEmitoxantrone

商标名

NovantroneNovantronMitox

IUPAC传统名

mitoxantrone

IUPAC标准名

1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-dihydroanthracene-9,10-dione

国际非专利药品(INN)

mitoxantronemitoxantronamitoxantronum

名称和标识

数据登录号

PubChem CID

4212

PubChem SID

1609645374650460856352855

CAS号

65271-80-970476-82-3

专利号

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

CHEMBL

CHEMBL58

CHEBI ID

CHEBI:50729CHEBI:43919CHEBI:6955

UniProt数据库

Q5MB13O07549P9WI81Q9UNQ0O07550

PDB数据库

4g0v2kgp4i416vxi7nfd2fum6gh9

维基百科标题

Mitoxantrone

BRENDA数据库

5.6.2.21.11.1.141.17.1.13.1.3.487.6.2.22.7.11.184.2.99.181.1.1.1841.11.1.71.6.2.4

BRENDA Ligand数据库

22650011262229661132934229662224533127071228546125891

BKMS React数据库

22854611262127071125891226500229661224533132934229662

MetaboLights数据库

MTBLS2145MTBLS379MTBLS2871MTBLS2825MTBLS417MTBLS2384MTBLS743

DrugBank ID

DB01204

ACToR数据库

65271-80-9137635-96-2

LINCS数据库

LSM-2481

IntAct数据库

EBI-28949089

KEGG ID

C11195

Drug Central Database

BindingDB数据库

PDBeChem数据库

KEGG DRUG Database

SureChEMBL数据库

Beilstein号

EnzymePortal数据库

CompTox数据库

数据登录号

化合物性质

药理学性质

Topoisomerase

安全信息

-20°C

-20°C Freezer

Refrigerator

下载链接

产品相关信息

Free Base

下载链接

化合物性质

分子相关蛋白质

分子相关蛋白质

分子图谱

暂无数据

点击上传数据

描述信息

Selleck Chemicals

S2485

Research Area: Cancer
Biological Activity:
Mitoxantrone Hydrochloride (NSC301739; Immunex) is a hydrochloride salt of mitoxantrone which is a synthetic antineoplastic anthracenedione (IC50 = 0.42 mM).Mitoxantrone Hydrochloride (NSC301739; Immunex) is also a synthetic antineoplastic anthracenedione. Mitoxantrone Hydrochloride (NSC301739; Immunex) is a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone Hydrochloride (NSC301739; Immunex) also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. Mitoxantrone Hydrochloride (NSC301739; Immunex) has a cytocidal effect on both proliferating and nonproliferating cultured human cells, suggesting lack of cell cycle phase specificity. [1][2]

DrugBank

DB01204

Drug Groups

approved; investigational

Description

An anthracenedione-derived antineoplastic agent. [PubChem]

Indication

For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis

Pharmacology

Mitoxantrone has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2.

Toxicity

Severe leukopenia with infection.

Affected Organisms

Humans and other mammals

Biotransformation

Hepatic

Absorption

Poorly absorbed following oral administration

Half Life

75 hours

Protein Binding

78%

Distribution

* 1000 L/m2

Clearance

* 21.3 L/hr/m2 [Elderly patients with breast cancer receiving IV administration of 15-90 mg/m2]
* 28.3 L/hr/m2 [Non-elderly patients with nasopharyngeal carcinoma receiving IV administration of 15-90 mg/m2]
* 16.2 L/hr/m2 [Non-elderly patients with malignant lymphoma receiving IV administration of 15-90 mg/m2]

References

• Fox EJ: Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther. 2006 Apr;28(4):461-74. [Pubmed]

External Links

• [Wikipedia]

• [RxList]

• [Drugs.com]

TRC

M373425

Mitoxantrone is a DNA intercalating drug. Mitoxantrone inhibits DNA synthesis. Mitoxantrone is used as an anti-cancer agent.

M373426

Mitoxantrone is a DNA intercalating drug. Mitoxantrone inhibits DNA synthesis. Mitoxantrone is used as an anti-cancer agent.

ChEBI

CHEBI:50729

A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.

描述信息

参考文献

PubChem文献

数据源提供

• Fox EJ: Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther. 2006 Apr;28(4):461-74. Pubmed

• Parker C et al. Lancet. 2010 Dec 11;376(9757)

• Beijnen, J.H., et al.: Anal. Profiles Drug Subs., 17, 221 (1984)

• McDonald, M., et al.: Drugs Exp. Clin. Res., 10, 745 (1984)

• Beijnen, J.H., et al.: Anal. Profiles Drug Subs., 17, 221 (1984)

• McDonald, M., et al.: Drugs Exp. Clin. Res., 10, 745 (1984)

参考文献

生物活性

PubChem BioAssay

生物活性

化合物信息

ID:1074